Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:55 PM ET 10-Q
Financial Results Edgemode, Inc. EDGM

Edgemode Q3 2026 Results: Net Loss of $1.37M

Edgemode, Inc. reported a net loss of $10.5 million for the nine months ended September 30, 2026, compared to a loss of $14.4 million in the prior year period. The company's balance sheet shows a significant stockholders' deficit of $7.6 million and a substantial reduction in derivative liabilities from $15.4 million to $1.5 million during the year.

Key figure
Net loss $1.37M
4:55 PM ET 10-Q
Financial Results American Strategic Investment Co. NYC

American Strategic Investment Q3 2026 Results: Net Loss of $6.72M

American Strategic Investment Co. reported a net loss of $22.8 million for the nine months ended September 30, 2026, compared to a $14.5 million loss in the prior year. The company's total equity decreased to $47.3 million from $64.8 million at year-end 2025, primarily driven by the net loss and offset by common stock issuances to its Advisor.

Key figure
Net loss $6.72M
4:54 PM ET Form 4
Insider Selling 10x Genomics, Inc. TXG

10x Genomics CEO Serge Saxonov Sells $1.95M of Stock

Serge Saxonov, CEO, sold 31,000 shares of 10x Genomics, Inc. at $62.90 a share, worth $1.95M in total on Nov 10, 2026. Shares held after the trade: 1,019,249 (-3.0%).

Value
$1.95M
Shares
31,000
Price
$62.90
Role
CEO
Holding change
-3.0%
Trade date
Nov 10, 2026
4:53 PM ET 8-K
Other 8-K Filing Santander Holdings USA, Inc. SNUS-PH

Santander Holdings USA Other 8-K Filing

Santander Holdings USA, Inc. is recasting its historical financial statements for 2023, 2024, and 2025 to reflect changes in its internal management reporting structure. The company combined its Commercial & Industrial and Commercial Real Estate segments into a single Commercial Banking segment, and this filing provides the recast segment data for informational purposes without restating overall consolidated results.

4:53 PM ET 10-Q
Financial Results Hines Global Income Trust, Inc. HGIT

Hines Global Income Trust Q3 2026 Results: Net Loss of $21.3M, Loss Widens

This document is a formal consent from Altus Group U.S., Inc. allowing Hines Global Income Trust, Inc. to reference their role as an independent valuer in the company's Q3 2026 Quarterly Report. It specifically pertains to the valuation process described in the Net Asset Value section of the filing.

Key figure
Net loss $21.3M
4:52 PM ET 10-Q
Financial Results Origin Investment Corp I ORIQ

Origin Investment Corp I Q3 2026 Results: Net Income $391K, Up 1.9% YoY

Origin Investment Corp I reported a net income of $1,165,890 for the nine months ended September 30, 2026, primarily driven by $1,937,643 in interest income from its Trust Account. As a blank check company, it has not yet commenced operations or generated revenue, and its total assets of $73.36 million are largely comprised of investments held in trust for a future business combination.

Key figure
Net income $391K · +1.9% YoY
4:52 PM ET 8-K
Financial Results Cerenome, Inc. CNSY

Cerenome Financial Results

Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.

Term
Q3 2026

“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”

Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
4:52 PM ET 10-Q
Financial Results Ckx Lands, Inc. CKX

Ckx Lands Q3 2026 Results: Net Income $444K, Up 167.0% YoY

CKX Lands, Inc. reported net income of $621,499 for the nine months ended September 30, 2026, an increase from $442,919 in the prior year period, driven largely by higher surface revenue and interest income. Total assets remained stable at approximately $22.4 million, while the company maintained a strong liquidity position with $15.9 million in cash and cash equivalents.

Key figure
Net income $444K · +167.0% YoY
4:52 PM ET 8-K
Financial Results Seritage Growth Properties SRG

Seritage Growth Properties Financial Results

Seritage Growth Properties reported Q3 2026 financial results, achieving net income of $2.7 million compared to a net loss for the nine-month period. The company generated $3.0 million from asset sales and received an $8.9 million distribution from an unconsolidated entity, while continuing to evaluate strategic options for its remaining portfolio.

Term
Q3 2026

“Although we have no new transactions under contract, we continue to work on both individual asset sales and potential strategic options for the portfolio and the Company”

Adam Metz, CEO & President
4:50 PM ET 8-K
Loan & Debt Apollo Global Management, Inc. APO

Apollo Global Management $600M Debt Financing with U.S. Bank Trust Company, National Association

Apollo Global Management issued $600 million in 7.550% Fixed-Rate Resettable Junior Subordinated Notes due 2056. The notes were issued under an indenture with U.S. Bank Trust Company as trustee and will bear a fixed rate until 2036, after which the rate will reset based on the Five-Year U.S. Treasury Rate plus a spread. Proceeds will be used for general corporate purposes, including a previously announced investment in Mubadala Capital Asset Management.

Value
$600M
Counterparty
U.S. Bank Trust Company, National Association
Term
30 years
4:50 PM ET 10-Q
Financial Results Grown Rogue International Inc. GRUSF

Grown Rogue International Q3 2026 Results: Net Loss of $8.89M

Grown Rogue International Inc. reported total revenue of $31.45 million for the nine months ended September 30, 2026, compared to $23.67 million in the prior year period. The company experienced a net loss of $12.58 million for the nine-month period, primarily driven by a $5.03 million loss on the acquisition of Rogue EBC and significant increases in general and administrative expenses.

Key figure
Net loss $8.89M
4:49 PM ET 8-K
Financial Results American Strategic Investment Co. NYC

American Strategic Investment Financial Results

American Strategic Investment Co. reported third quarter 2026 revenue of $7.1 million and a net loss of $6.7 million. The results reflect a decrease in revenue compared to the prior year due to the disposition of the 1140 Avenue of the Americas property. Subsequent to the quarter, the company signed a major lease extension and expansion with the State of New York at its 123 William Street property.

“The Company’s results this quarter build on the progress we made over the last two quarters, as our capital prioritization strategy continues to contribute to our results. The portfolio’s high quality, largely investment grade tenant base continues to support stable performance this year.”

Nicholas Schorsch, Jr., CEO of ASIC

“We remain focused on completing our remaining asset dispositions and directing capital toward the opportunities we believe will create the most durable value for our shareholders, such as the execution of the lease with the State of New York after the end of the quarter that increases pro-forma occupancy at 123 William Street to approximately 75% and portfolio occupancy to approximately 78%.”

Nicholas Schorsch, Jr., CEO of ASIC
4:49 PM ET Form 4
Insider Selling Nebius Group N.V. NBIS

Nebius Group Chief Revenue Officer Marc Boroditsky Sells $1.04M of Stock

Marc Boroditsky, Chief Revenue Officer, sold 7,000 shares of Nebius Group N.V. at $147.97 a share, worth $1.04M in total on Nov 11, 2026. Shares held after the trade: 0 (-100.0%).

Value
$1.04M
Shares
7,000
Price
$147.97
Role
Chief Revenue Officer
Holding change
-100.0%
Trade date
Nov 11, 2026
4:49 PM ET 8-K
M&A Deal Hall Chadwick Acquisition Corp HCAC

Hall Chadwick Acquisition Signs $400M M&A Deal with REEcycle Holdings, Inc.

Hall Chadwick Acquisition Corp. (HCAC) announced that the SEC has declared effective its Form S-4 registration statement for its proposed $400 million business combination with REEcycle Holdings, Inc. A shareholder meeting to vote on the merger is scheduled for December 10, 2026, with the deal expected to close by year-end. Upon completion, REEcycle will become a Nasdaq-listed company focused on domestic rare-earth element recycling technology.

Value
$400M
Counterparty
REEcycle Holdings, Inc.
4:49 PM ET 8-K
Loan & Debt Qualcomm Inc QCOM

Qualcomm $4B Debt Financing with U.S. Bank Trust Company, National Association

Qualcomm Incorporated executed an Officers' Certificate for the issuance and sale of $4.0 billion in aggregate principal amount of senior unsecured notes across five tranches maturing between 2028 and 2036. The notes carry interest rates ranging from 5.000% to 5.800% and rank equally with the company's other senior debt. The offering was conducted through an underwriting agreement with a syndicate of banks including BNP Paribas, BofA Securities, and J.P. Morgan.

Value
$4B
Counterparty
U.S. Bank Trust Company, National Association
Term
through Nov 2036
4:48 PM ET 8-K
Financial Results Femasys Inc FEMY

Femasys Financial Results

Femasys reported financial results for the third quarter of 2026, highlighting a slight increase in U.S. sales to $0.35 million despite overall sales declining due to international distributor order timing. The company completed a $30 million private placement in August to fund the build-out of its U.S. commercial team and support the FemBloc pivotal trial.

Term
Q3 2026

“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys.”

Kathy Lee-Sepsick, Founder and Chief Executive Officer

“These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”

Kathy Lee-Sepsick, Founder and Chief Executive Officer
4:48 PM ET 8-K
Stock Buyback Xylem Inc. XYL

Xylem Announces $1.5B Stock Buyback

Xylem Inc.'s Board of Directors has authorized a new share repurchase program to buy back up to $1.5 billion of its common stock. The program has no expiration date and allows for purchases in the open market or through other means at the company's discretion. This authorization signals management's confidence in the company's value and its commitment to returning capital to shareholders.

Value
$1.5B
4:48 PM ET 10-Q
Financial Results AB Private Credit Investors Corp

AB Private Credit Investors Q3 2026 Results: Net Income $18.8M, Up 9.2% YoY

For the nine months ended September 30, 2026, AB Private Credit Investors Corp reported net investment income after tax of $47.9 million, a significant increase from $42.3 million in the prior year period. However, net assets resulting from operations decreased to $24.2 million from $41.7 million year-over-year, primarily due to $22.3 million in net unrealized depreciation on investments.

Key figure
Net income $18.8M · +9.2% YoY
4:48 PM ET 8-K
Financial Results NextPlat Corp NXPL

NextPlat Financial Results

NextPlat Corp reported third quarter 2026 financial results featuring a 35% improvement in gross profit and a 66% reduction in net loss. While consolidated revenue decreased to $10.5 million due to lower reimbursement rates, the company saw 300% growth in high-margin pharmacy contract revenue, specifically driven by 340B services.

Term
Q3 2026

“Our third quarter results reflect continued year-over-year improvement across the business, driven by the refocusing of our healthcare operations on high-value, high-margin services designed to deliver consistent bottom-line results in what remains a dynamic market.”

David Phipps, Chief Executive Officer and President of NextPlat Corp

“Our focus remains on growth and profitability through our differentiated, high-value healthcare services and expanding community pharmacy network, including our new Scott’s location near Pensacola and a new pharmacy in Jacksonville, supported by a more efficient operating structure.”

David Phipps, Chief Executive Officer and President of NextPlat Corp
4:47 PM ET 10-Q
Financial Results Crescent Private Credit Income Corp

Crescent Private Credit Income Q3 2026 Results: Net Income $14.3M, Up 115.9% YoY

Crescent Private Credit Income Corp reported total investment income of $62.2 million for the nine months ended September 30, 2026, a significant increase from $30.8 million in the prior year period. Net investment income rose to $33.2 million, though the company recorded net realized and unrealized losses on investments during the period.

Key figure
Net income $14.3M · +115.9% YoY
4:47 PM ET 10-Q
Financial Results Seritage Growth Properties SRG

Seritage Growth Properties Q3 2026 Results: Turns Profitable, Net Income $3.96M

Seritage Growth Properties continued its strategic plan to liquidate its real estate portfolio, focusing on asset dispositions to retire outstanding debt. The filing reflects a decrease in rental income as properties are sold, consistent with the company's transition toward dissolution.

Key figure
Net income $3.96M
4:47 PM ET 10-Q
Financial Results Farmers & Merchants Bancshares, Inc. FMFG

Farmers & Merchants Bancshares Q3 2026 Results: Net Income $2.02M, Up 18.7% YoY

Farmers & Merchants Bancshares, Inc. reported net income of $5.75 million for the nine months ended September 30, 2026, an increase from $4.07 million in the prior year period. The company saw a significant rise in net interest income to $20.7 million, driven by higher loan yields and a decrease in interest expense on deposits.

Key figure
Net income $2.02M · +18.7% YoY
4:47 PM ET 10-Q
Financial Results Biofrontera Inc. BFRI

Biofrontera Q3 2026 Results: Net Loss of $6.42M, Loss Narrows

Biofrontera Inc. reported a net loss of $11.8 million for the nine months ended September 30, 2026, an improvement from the $16.2 million loss in the prior year period. Product revenues grew significantly to $31.2 million compared to $24.6 million in 2025, while the company's cash position decreased to $3.2 million as of the reporting date.

Key figure
Net loss $6.42M
4:46 PM ET 8-K
Other 8-K Filing Apnimed, Inc. APMD

Apnimed Other 8-K Filing

Apnimed, Inc. announced that its previously issued financial statements for the three and six months ended June 30, 2026, should no longer be relied upon due to an accounting error. The error involves the misclassification of an $85.4 million gain from the sale of its interest in Shionogi-Apnimed Sleep Science, LLC as continuing operations rather than discontinued operations. The company intends to file a restatement on Form 10-Q/A to correct the classification, which does not impact total net income, cash, or total assets.

Counterparty
Shionogi & Co., Ltd.
4:46 PM ET 8-K/A
Executive Compensation Radian Group Inc RDN

Radian Group Executive Compensation

Radian Group Inc. approved compensation for Daniel Kobell following his appointment as Senior Executive Vice President and CFO, including an annual base salary of $525,000 and a target short-term incentive of 100% of base salary. He was also granted $250,000 in time-based restricted stock units to recognize his service as Interim CFO since February 2026. His 2027 long-term equity incentive target was set at $1.7 million.

Counterparty
Daniel Kobell
4:46 PM ET 8-K
Shareholder Meeting Gulf Resources, Inc. GURE

Gulf Resources Shareholder Meeting

Gulf Resources held its 2026 Annual Meeting of Stockholders on November 11, 2026, where shareholders elected seven directors to the board for one-year terms. Stockholders also ratified GGF CPA LTD. as independent auditors, approved an amendment to the 2025 Stock Incentive Plan, and approved executive compensation in an advisory vote.

4:46 PM ET Form 4
Insider Selling Macom Technology Solutions Holdings, Inc. MTSI

Macom Technology Solutions Holdings President and CEO Stephen G. Daly Sells $14.7M of Stock

Stephen G. Daly, President and CEO, sold 59,939 shares of Macom Technology Solutions Holdings, Inc. at $240.29 to $252.61 a share (average $245.12) in 12 transactions, worth $14.7M in total on Nov 11, 2026. Shares held after the trade: 39,239 (-6.4%).

Value
$14.7M
Shares
59,939
Average price
$245.12
Role
President and CEO
Holding change
-6.4%
Trade date
Nov 11, 2026
4:46 PM ET 8-K
Leadership Change Taboola.com Ltd. TBLA

Taboola.com Leadership Change

Monica Mijaleski resigned from the Board of Directors of Taboola.com Ltd. effective November 6, 2026. The company stated her departure was not due to any dispute or disagreement regarding operations, policies, or practices.

4:45 PM ET 10-Q
Financial Results KKR Infrastructure Conglomerate LLC

KKR Infrastructure Conglomerate Q3 2026 Results: Net Income $300M, Up 144.8% YoY

For the nine months ended September 30, 2026, KKR Infrastructure Conglomerate LLC reported a net increase in net assets resulting from operations of $558.0 million, driven by $589.2 million in unrealized appreciation on investments. Total assets grew to $9.22 billion from $6.59 billion at year-end 2025, reflecting significant capital deployment and investment performance.

Key figure
Net income $300M · +144.8% YoY
4:45 PM ET 10-Q
Financial Results Palomino Laboratories Inc. PALX

Palomino Laboratories Q3 2026 Results: Net Loss of $4.42M, Loss Widens

Palomino Laboratories Inc. reported a net loss of $7.03 million for the nine months ended September 30, 2026, compared to a $2.42 million loss in the prior year, driven by a significant increase in R&D and G&A expenses. The company strengthened its balance sheet during the period, ending the quarter with $17.79 million in cash and cash equivalents.

Key figure
Net loss $4.42M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.